Pancreatic steatosis is associated with exocrine pancreatic dysfunction in children with MASLD: a prospective cross-sectional study Authors: Buket Daldaban Sarıca, Ümmügülsüm Özgül Gümüş, Leyla Kara, Ebru Gök, Serkan Bilge Koca, Tarık Kırkgöz Published: 2026 ABSTRACT ObjectiveThis study aimed to evaluate the relationship between pancreatic steatosis and fecal elastase (FE) levels in children with hepatic steatosis, compare clinical, metabolic, and imaging findings according to metabolic dysfunction-associated steatotic liver disease (MASLD) status, and determine whether this relationship persists within children with MASLD.MethodsThis prospective cross-sectional study was conducted in the Pediatric Gastroenterology and Pediatric Endocrinology Departments of Kayseri City Hospital. Participants were classified according to the presence of MASLD. Clinical characteristics, anthropometric measurements, metabolic parameters, ultrasonographic findings, and FE levels were compared between groups. FE levels were categorized as normal (> 200 µg/g), low (100–200 µg/g), and severely low (< 100 µg/g). For binary analyses, low FE was defined as ≤ 200 µg/g. Logistic regression analyses were performed to identify factors associated with low FE levels and high-grade pancreatic steatosis. Analyses were also performed within the MASLD group. Receiver operating characteristic curve analyses were used to assess the discriminatory performance of clinical, metabolic, and imaging-based parameters.ResultsA total of 163 children were included; 92 were classified as having MASLD and 71 were classified as non-MASLD. Pancreatic steatosis was significantly more frequent in the MASLD group than in the non-MASLD group (93.5% vs. 40.8%), and low FE levels were also more prevalent (59.8% vs. 15.5%; p < 0.001). In multivariable analysis of the overall cohort, pancreatic steatosis grade (OR: 1.97, 95% CI: 1.20–3.23, p = 0.007) and waist circumference (WC) ≥95th percentile (OR: 3.31, 95% CI: 1.24–8.87, p = 0.017) were independently associated with low FE levels. Within the MASLD group, pancreatic steatosis grade was significantly associated with low FE levels. Pancreatic steatosis grade showed the highest discriminatory performance for low FE levels among the evaluated parameters (AUC = 0.76).ConclusionsPancreatic steatosis was more frequent in children with MASLD, and its severity was associated with low FE levels both in the overall cohort and within the MASLD group. Imaging-based pancreatic findings showed moderate discriminatory performance for low FE levels but should not be interpreted as validated diagnostic thresholds. Pancreatic steatosis may represent a clinically relevant feature of pediatric MASLD in relation to possible subclinical alterations in exocrine pancreatic function.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12887-026-07464-4. Background Metabolic dysfunction-associated steatotic liver disease (MASLD) represents an important spectrum of liver disease linked to metabolic dysfunction, with a rapidly increasing prevalence among children and adolescents [1]. In recent years, the terminology of the disease has evolved from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) and ultimately to MASLD, reflecting a stronger emphasis on its metabolic basis [2]. This conceptual shift has also been adopted in the pediatric population, where MASLD is considered a systemic disease closely associated with obesity and insulin resistance [3]. It is increasingly recognized that MASLD can affect not only the liver but also other metabolically active organs [3]. In this context, pancreatic steatosis has emerged as a relevant phenotype associated with components of the metabolic syndrome. Studies in adults have demonstrated strong associations between pancreatic steatosis, obesity, and hepatic steatosis; in fact, it has been reported that hepatic steatosis is one of the major predictors of pancreatic steatosis [4]. While international consensus reports consider pancreatic steatosis to be part of the spectrum of metabolic diseases, they emphasize that significant gaps in knowledge regarding its clinical outcomes persist [5]. The vast majority of pediatric studies on pancreatic steatosis have focused primarily on the endocrine aspects of the disease and its association with insulin resistance [6, 7]. However, despite growing evidence regarding the interaction between exocrine pancreatic function and metabolic processes [8–10], the role of exocrine pancreatic function has been studied to a limited extent. Although FE is a non-invasive marker commonly used to assess exocrine pancreatic function [11], data examining the relationship between this parameter and pancreatic steatosis in pediatric MASLD are scarce. Furthermore, it is not yet clear whether the association between imaging-based findings and low fecal elastase (FE) levels is observed within children with MASLD, or whether this association is primarily driven by differences in metabolic burden between the groups. This study aimed to evaluate the relationship between pancreatic steatosis and FE levels in children with hepatic steatosis, to compare clinical, metabolic, and imaging-based findings according to MASLD status, and to investigate whether this relationship persists within children with MASLD. Methods Study design and participants Ethics committee approval was obtained from the Clinical Research Ethics Committee of Kayseri City Hospital on January 14, 2026 (decision no. 752). The study included pediatric patients followed at University of Health Sciences, Kayseri City Hospital, Departments of Pediatric Gastroenterology Hepatology and Nutrition and Pediatric Endocrinology, for whom complete clinical, laboratory, and imaging data were available. The non-MASLD group consisted of children with hepatic steatosis detected by imaging who did not meet the cardiometabolic criteria required for a MASLD diagnosis. All cases were evaluated for viral hepatitis, autoimmune hepatitis, Wilson’s disease, alpha-1 antitrypsin deficiency, and celiac disease; adolescents were also screened for alcohol use and potential drug-induced liver injury. Cases in whom these conditions were ruled out were included in the study. Patients with missing data, known pancreatic disease, a history of acute pancreatitis, and individuals with systemic diseases that could affect pancreatic function, including type 1 diabetes mellitus, cystic fibrosis, and celiac disease, were excluded from the study. Diagnostic criteria for MASLD The diagnosis of MASLD was made based on the presence of cardiometabolic risk factors and the exclusion of alternative etiologies, following the demonstration of hepatic steatosis via imaging methods [3]. Pediatric cardiometabolic risk criteria were assessed as the presence of at least one metabolic risk factor in addition to a body mass index (BMI) ≥ the 85th percentile (BMI standard deviation scores (BMI SDS) of ≥ + 1), or an age- and sex-adjusted waist circumference (WC) ≥ the 95th percentile [3]. Metabolic risk abnormalities were defined as follows: (i) Impaired glucose metabolism: fasting serum glucose ≥100 mg/dL, random serum glucose ≥200 mg/dL, glycated hemoglobin (HbA1c) ≥5.7%, diagnosis of type 2 diabetes, or treatment for type 2 diabetes.(ii) High blood pressure: in children aged <13 years, blood pressure ≥ the 95th percentile for age, sex, and height or ≥130/80 mmHg, whichever is lower; in children aged ≥13 years, blood pressure ≥130/85 mmHg; or use of antihypertensive treatment. (iii) Hypertriglyceridemia: plasma triglyceride level ≥100 mg/dL in children aged <10 years, ≥150 mg/dL in children aged ≥10 years; or use of lipid-lowering therapy.(iv) Low HDL-C: HDL-C level ≤40 mg/dL; or use of lipid-lowering therapy. (i) Impaired glucose metabolism: fasting serum glucose ≥100 mg/dL, random serum glucose ≥200 mg/dL, glycated hemoglobin (HbA1c) ≥5.7%, diagnosis of type 2 diabetes, or treatment for type 2 diabetes. (i) Impaired glucose metabolism: fasting serum glucose ≥100 mg/dL, random serum glucose ≥200 mg/dL, glycated hemoglobin (HbA1c) ≥5.7%, diagnosis of type 2 diabetes, or treatment for type 2 diabetes. (ii) High blood pressure: in children aged <13 years, blood pressure ≥ the 95th percentile for age, sex, and height or ≥130/80 mmHg, whichever is lower; in children aged ≥13 years, blood pressure ≥130/85 mmHg; or use of antihypertensive treatment. (ii) High blood pressure: in children aged <13 years, blood pressure ≥ the 95th percentile for age, sex, and height or ≥130/80 mmHg, whichever is lower; in children aged ≥13 years, blood pressure ≥130/85 mmHg; or use of antihypertensive treatment. (iii) Hypertriglyceridemia: plasma triglyceride level ≥100 mg/dL in children aged <10 years, ≥150 mg/dL in children aged ≥10 years; or use of lipid-lowering therapy. (iii) Hypertriglyceridemia: plasma triglyceride level ≥100 mg/dL in children aged <10 years, ≥150 mg/dL in children aged ≥10 years; or use of lipid-lowering therapy. (iv) Low HDL-C: HDL-C level ≤40 mg/dL; or use of lipid-lowering therapy. (iv) Low HDL-C: HDL-C level ≤40 mg/dL; or use of lipid-lowering therapy. Clinical and anthropometric assessment Demographic and clinical data were recorded at the time of study enrollment. Anthropometric assessments were recorded using standardized methods. BMI (kg/m²) was computed, and BMI SDS were obtained according to reference data adjusted for age and sex [12]. Central obesity was evaluated by measuring WC across all participants, and WC SDS were derived based on reference values established for Turkish children [13]. Laboratory measurements Serum glucose, insulin, HbA1c, triglycerides, HDL-C, low-density lipoprotein cholesterol (LDL-C), total cholesterol, and alanine aminotransferase (ALT) levels were measured in blood specimens obtained from each participant after fasting. Insulin resistance was calculated using the homeostatic model assessment index (HOMA-IR). FE levels were assessed in a single stool sample collected from the patients included in the study. Although none of the patients reported watery stools or acute diarrhea at the time of sample collection, stool consistency was not systematically recorded using a standard scoring system, and no standardized protocol was applied for sampling time or stool weight. FE levels, as a non-invasive marker of exocrine pancreatic function, were measured using enzyme-linked immunosorbent assay with a kit manufactured by Immundiagnostik AG (Bensheim, Germany), according to the manufacturer’s instructions. FE levels were defined as normal (> 200 µg/g), low (100–200 µg/g), and severely low (< 100 µg/g) [11]. Imaging assessment All participants underwent abdominal ultrasonography performed by an experienced radiologist who was unaware of the clinical and laboratory data. Hepatic steatosis was graded semi-quantitatively on a scale of 1–3 according to standard ultrasonographic criteria, corresponding to mild, moderate, and severe steatosis, respectively. Due to the lack of validated imaging criteria in children, pancreatic echogenicity was classified into four grades using a previously described ultrasonographic grading system [14]. In the normal (Grade 0) state, pancreatic echogenicity is similar to that of the liver; in the presence of hepatic steatosis, the kidney or spleen was used as a reference. A mild increase with well-defined borders was classified as Grade 1, while a more pronounced increase in echogenicity accompanied by blurring of the borders was classified as Grade 2. Echogenicity reaching or exceeding the level of retroperitoneal fat, inability to distinguish pancreatic borders, and inability to visualize vascular structures were defined as Grade 3. To assess intraobserver reliability, the ultrasound findings of 9 randomly selected patients were re-evaluated by the same radiologist. In addition, to assess interobserver agreement, the images of 6 patients were independently evaluated by a second radiologist experienced in abdominal ultrasonography. In the intraobserver assessment of hepatic steatosis grading, agreement was achieved in 8 of 9 patients, and the weighted kappa coefficient was calculated as 0.82. Complete intraobserver agreement was observed for pancreatic steatosis grading. In the interobserver assessment, complete agreement was observed for both hepatic and pancreatic steatosis grading in all 6 evaluated patients. Statistical analysis Statistical analyses were performed using IBM SPSS Statistics (version 31.0.0.0). Continuous variables were expressed as median (interquartile range), and categorical variables as number (percentage). Mann–Whitney U test was applied to compare continuous variables between the two groups, and the Pearson chi-square test was used for categorical variables. The Pearson chi-square test was used for comparisons of categorical variables across multiple groups. When expected cell frequencies were insufficient, the Fisher–Freeman–Halton exact test with Monte Carlo simulation was applied. Following a significant overall comparison, pairwise comparisons were performed with Bonferroni correction. Correlation analyses were conducted using Spearman’s rank correlation coefficient. Logistic regression models were performed to determine variables associated with low FE levels and high-grade pancreatic steatosis (Grade 2–3). The enter method was used in univariate logistic regression analyses to identify factors associated with low FE levels and high-grade pancreatic steatosis. Variables with a p value < 0.20 in univariate analysis and clinically relevant variables were included in the multiple logistic regression model using the backward Wald elimination method. Results were presented as odds ratios (OR) with 95% confidence intervals (CI). In children with MASLD, factors associated with low FE levels and high-grade pancreatic steatosis were evaluated using univariate logistic regression. Spearman correlation analyses and comparisons across FE categories were also performed. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of clinical and imaging parameters, and optimal cut-off values were determined using the Youden index. A p value < 0.05 was considered statistically significant. Results Children with and without MASLD did not differ significantly in age (p = 0.25); however, male sex was more frequent in the MASLD group (p = 0.007). Anthropometric measures, including BMI, BMI SDS, and WC, were significantly higher among children with MASLD (all p < 0.001). Systolic and diastolic blood pressure levels were also significantly elevated in this group (both p < 0.001). Regarding metabolic parameters, children with MASLD had higher triglyceride, HbA1c, plasma glucose, and HOMA-IR levels, together with lower HDL-C levels (all p < 0.05). In contrast, total cholesterol and LDL-C levels were comparable between the groups. ALT levels were significantly higher in the MASLD group (p < 0.001), whereas thyroid function tests did not differ significantly. Pancreatic steatosis was substantially more frequent and more severe in children with MASLD than in those without MASLD (p < 0.001). In addition, low FE levels were observed more frequently in the MASLD group (p < 0.001) (Table 1). Table 1Clinical, laboratory and imaging characteristics of children according to MASLD statusVariablesNon-MASLD (n = 71)MASLD (n = 92) p Age (years)11 (5)12 (3)0.250Sex0.007 Female39 (54.9)31 (33.7) Male32 (45.1)61 (66.3)Anthropometric parameters BMI (kg/m²)20.0 (2.0)30.76 (6.92)< 0.001 BMI SDS0.60 (0.40)2.98 (0.80)< 0.001 WC (cm)64.0 (7.0)102.0 (16.0)< 0.001Waist circumference category< 0.001 < 95th percentile71 (100.0)0 (0.0) ≥ 95th percentile0 (0.0)92 (100.0)Blood pressure parameters Systolic blood pressure (mmHg)120.0 (15.0)130.0 (18.75)< 0.001 Diastolic blood pressure (mmHg)73.0 (8.0)78.0 (14.0)< 0.001Blood pressure category< 0.001 < 95th percentile71 (100.0)0 (0.0) ≥ 95th percentile0 (0.0)92 (100.0)Lipid and metabolic parameters Total cholesterol (mg/dL)158.0 (46.0)159.5 (46.75)0.197 Triglycerides (mg/dL)109.0 (47.0)135.5 (78.5)< 0.001Triglyceride category< 0.001 Normal65 (91.5)51 (55.4) High6 (8.5)41 (44.6) HDL-C (mg/dL)46.0 (9.0)39.0 (8.5)< 0.001 LDL-C (mg/dL)96.0 (32.0)96.5 (38.25)0.480 ALT (U/L)18.0 (13.0)39.0 (48.0)< 0.001 Fasting insulin (µIU/mL)19.0 (12.8)22.65 (17.73)0.015 HOMA-IR3.87 (2.99)4.98 (4.12)0.001 HbA1c (%)5.3 (0.4)5.7 (0.3)< 0.001 Fasting plasma glucose (mg/dL)86.0 (9.0)90.0 (13.75)0.021Thyroid function tests TSH (µIU/mL)2.39 (1.10)2.22 (1.46)0.399 Free T4 (ng/dL)12.3 (2.4)12.75 (2.7)0.699Ultrasonographic findingsHepatic steatosis grade< 0.001 Grade 169 (97.2)8 (8.7) Grade 22 (2.8)31 (33.7) Grade 30 (0.0)53 (57.6)Pancreatic steatosis< 0.001 No42 (59.2)6 (6.5) Yes29 (40.8)86 (93.5)Pancreatic steatosis grade< 0.001 Grade 042 (59.2)6 (6.5) Grade 126 (36.6)18 (19.6) Grade 23 (4.2)49 (53.3) Grade 30 (0.0)19 (20.7)FE category< 0.001 Normal FE (> 200 µg/g)60 (84.5)37 (40.2) Low FE (100–200 µg/g)7 (9.9)34 (37.0) Severely low FE (< 100 µg/g)4 (5.6)21 (22.8)Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Comparisons between groups were performed using the Mann–Whitney U test for continuous variables and the Pearson chi-square test for categorical variables. High triglyceride status was defined as triglyceride level ≥150 mg/dL. A p value <0.05 was considered statistically significantALT alanine aminotransferase, BMI body mass index, BMI SDS body mass index standard deviation score, FE fecal elastase, Free T4 free thyroxine, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, LDL-C low-density lipoprotein cholesterol, MASLD metabolic dysfunction-associated steatotic liver disease, TSH thyroid-stimulating hormone, WC waist circumference Table 1Clinical, laboratory and imaging characteristics of children according to MASLD statusVariablesNon-MASLD (n = 71)MASLD (n = 92) p Age (years)11 (5)12 (3)0.250Sex0.007 Female39 (54.9)31 (33.7) Male32 (45.1)61 (66.3)Anthropometric parameters BMI (kg/m²)20.0 (2.0)30.76 (6.92)< 0.001 BMI SDS0.60 (0.40)2.98 (0.80)< 0.001 WC (cm)64.0 (7.0)102.0 (16.0)< 0.001Waist circumference category< 0.001 < 95th percentile71 (100.0)0 (0.0) ≥ 95th percentile0 (0.0)92 (100.0)Blood pressure parameters Systolic blood pressure (mmHg)120.0 (15.0)130.0 (18.75)< 0.001 Diastolic blood pressure (mmHg)73.0 (8.0)78.0 (14.0)< 0.001Blood pressure category< 0.001 < 95th percentile71 (100.0)0 (0.0) ≥ 95th percentile0 (0.0)92 (100.0)Lipid and metabolic parameters Total cholesterol (mg/dL)158.0 (46.0)159.5 (46.75)0.197 Triglycerides (mg/dL)109.0 (47.0)135.5 (78.5)< 0.001Triglyceride category< 0.001 Normal65 (91.5)51 (55.4) High6 (8.5)41 (44.6) HDL-C (mg/dL)46.0 (9.0)39.0 (8.5)< 0.001 LDL-C (mg/dL)96.0 (32.0)96.5 (38.25)0.480 ALT (U/L)18.0 (13.0)39.0 (48.0)< 0.001 Fasting insulin (µIU/mL)19.0 (12.8)22.65 (17.73)0.015 HOMA-IR3.87 (2.99)4.98 (4.12)0.001 HbA1c (%)5.3 (0.4)5.7 (0.3)< 0.001 Fasting plasma glucose (mg/dL)86.0 (9.0)90.0 (13.75)0.021Thyroid function tests TSH (µIU/mL)2.39 (1.10)2.22 (1.46)0.399 Free T4 (ng/dL)12.3 (2.4)12.75 (2.7)0.699Ultrasonographic findingsHepatic steatosis grade< 0.001 Grade 169 (97.2)8 (8.7) Grade 22 (2.8)31 (33.7) Grade 30 (0.0)53 (57.6)Pancreatic steatosis< 0.001 No42 (59.2)6 (6.5) Yes29 (40.8)86 (93.5)Pancreatic steatosis grade< 0.001 Grade 042 (59.2)6 (6.5) Grade 126 (36.6)18 (19.6) Grade 23 (4.2)49 (53.3) Grade 30 (0.0)19 (20.7)FE category< 0.001 Normal FE (> 200 µg/g)60 (84.5)37 (40.2) Low FE (100–200 µg/g)7 (9.9)34 (37.0) Severely low FE (< 100 µg/g)4 (5.6)21 (22.8)Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Comparisons between groups were performed using the Mann–Whitney U test for continuous variables and the Pearson chi-square test for categorical variables. High triglyceride status was defined as triglyceride level ≥150 mg/dL. A p value <0.05 was considered statistically significantALT alanine aminotransferase, BMI body mass index, BMI SDS body mass index standard deviation score, FE fecal elastase, Free T4 free thyroxine, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, LDL-C low-density lipoprotein cholesterol, MASLD metabolic dysfunction-associated steatotic liver disease, TSH thyroid-stimulating hormone, WC waist circumference Clinical, laboratory and imaging characteristics of children according to MASLD status Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Comparisons between groups were performed using the Mann–Whitney U test for continuous variables and the Pearson chi-square test for categorical variables. High triglyceride status was defined as triglyceride level ≥150 mg/dL. A p value <0.05 was considered statistically significant ALT alanine aminotransferase, BMI body mass index, BMI SDS body mass index standard deviation score, FE fecal elastase, Free T4 free thyroxine, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, LDL-C low-density lipoprotein cholesterol, MASLD metabolic dysfunction-associated steatotic liver disease, TSH thyroid-stimulating hormone, WC waist circumference Correlation analysis demonstrated a strong positive association between hepatic and pancreatic steatosis grades (r = 0.665). Hepatic steatosis grade was also strongly correlated with WC (r = 0.799) and BMI SDS (r = 0.746). FE levels showed moderate negative correlations with both hepatic steatosis grade (r = − 0.439) and pancreatic steatosis grade (r = − 0.408). Triglyceride levels were positively correlated with hepatic steatosis (r = 0.400) and, to a lesser extent, pancreatic steatosis grade (r = 0.277), whereas HDL-C demonstrated inverse correlations with both hepatic steatosis grade (r = − 0.378) and pancreatic steatosis grade (r = − 0.342) (Fig. 1). Fig. 1Correlation matrix of hepatic steatosis grade, pancreatic steatosis grade, fecal elastase, and metabolic parameters. Spearman’s rank correlation coefficient was used to assess correlations between variables. Correlation coefficients are shown in the cells, and statistically significant correlations are indicated in bold. The color scale represents the direction and strength of correlation, ranging from − 1 to + 1. FE: fecal elastase; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; WC: waist circumference; BMI SDS: body mass index standard deviation score Correlation matrix of hepatic steatosis grade, pancreatic steatosis grade, fecal elastase, and metabolic parameters. Spearman’s rank correlation coefficient was used to assess correlations between variables. Correlation coefficients are shown in the cells, and statistically significant correlations are indicated in bold. The color scale represents the direction and strength of correlation, ranging from − 1 to + 1. FE: fecal elastase; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; WC: waist circumference; BMI SDS: body mass index standard deviation score In univariate analysis, hepatic steatosis grade, pancreatic steatosis grade, BMI SDS, WC group, and triglyceride levels were significantly associated with low FE levels (all p < 0.05). In multivariable logistic regression analysis, pancreatic steatosis grade and WC remained independently associated with low FE levels. For each one-grade increase in pancreatic steatosis, the odds of low FE increased by approximately 1.97-fold (OR: 1.972, 95% CI: 1.204–3.231, p = 0.007). In addition, children with a WC ≥ 95th percentile had 3.31-fold higher odds of low FE than those with lower values (OR: 3.31, 95% CI: 1.235–8.871, p = 0.017). Other variables did not retain statistical significance after adjustment (Table 2). Table 2Univariate and multivariable logistic regression analyses of factors associated with low fecal elastase levelsVariableFE> 200 µg/g (n = 97)FE≤ 200 µg/g (n = 66)Univariate OR (95% CI) p Multivariable OR (95% CI) p Age, years11 (4)12 (4)1.142 (0.994–1.312)0.060——Sex Female46 (47.4)24 (36.4)Reference——— Male51 (52.6)42 (63.6)1.578(0.832–2.995)0.163——Hepatic steatosis grade1 (1)3 (1)2.937 (1.947–4.429)< 0.001——Pancreatic steatosis grade1 (1)2 (1)2.939 (1.986–4.352)< 0.0011.972 (1.204–3.231)0.007BMI SDS0.8 (2.23)2.73 (0.94)1.936 (1.462–2.565)< 0.001——WC category <95th percentile60 (61.9)11 (16.7)Reference—Reference— ≥95th percentile37 (38.1)55 (83.3)8.108 (3.769–17.444)< 0.0013.310 (1.235–8.871)0.017HOMA-IR4 (3.21)4.86 (4.14)1.024 (0.980–1.069)0.292——Triglycerides, mg/dL113 (57)137.5 (63.5)1.008 (1.002–1.014)0.012——HDL-C, mg/dL43 (10.5)39 (11.25)0.985 (0.952–1.019)0.389——Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Logistic regression analysis was performed to identify factors associated with low fecal elastase levels, defined as fecal elastase ≤200 µg/g. Variables with a p value <0.20 in univariate analysis were entered into the multivariable model, which was constructed using the backward Wald method. Odds ratios (ORs) are presented with 95% confidence intervals (CIs). A p value <0.05 was considered statistically significantBMI SDS body mass index standard deviation score, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, WC waist circumference Table 2Univariate and multivariable logistic regression analyses of factors associated with low fecal elastase levelsVariableFE> 200 µg/g (n = 97)FE≤ 200 µg/g (n = 66)Univariate OR (95% CI) p Multivariable OR (95% CI) p Age, years11 (4)12 (4)1.142 (0.994–1.312)0.060——Sex Female46 (47.4)24 (36.4)Reference——— Male51 (52.6)42 (63.6)1.578(0.832–2.995)0.163——Hepatic steatosis grade1 (1)3 (1)2.937 (1.947–4.429)< 0.001——Pancreatic steatosis grade1 (1)2 (1)2.939 (1.986–4.352)< 0.0011.972 (1.204–3.231)0.007BMI SDS0.8 (2.23)2.73 (0.94)1.936 (1.462–2.565)< 0.001——WC category <95th percentile60 (61.9)11 (16.7)Reference—Reference— ≥95th percentile37 (38.1)55 (83.3)8.108 (3.769–17.444)< 0.0013.310 (1.235–8.871)0.017HOMA-IR4 (3.21)4.86 (4.14)1.024 (0.980–1.069)0.292——Triglycerides, mg/dL113 (57)137.5 (63.5)1.008 (1.002–1.014)0.012——HDL-C, mg/dL43 (10.5)39 (11.25)0.985 (0.952–1.019)0.389——Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Logistic regression analysis was performed to identify factors associated with low fecal elastase levels, defined as fecal elastase ≤200 µg/g. Variables with a p value <0.20 in univariate analysis were entered into the multivariable model, which was constructed using the backward Wald method. Odds ratios (ORs) are presented with 95% confidence intervals (CIs). A p value <0.05 was considered statistically significantBMI SDS body mass index standard deviation score, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, WC waist circumference Univariate and multivariable logistic regression analyses of factors associated with low fecal elastase levels Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Logistic regression analysis was performed to identify factors associated with low fecal elastase levels, defined as fecal elastase ≤200 µg/g. Variables with a p value <0.20 in univariate analysis were entered into the multivariable model, which was constructed using the backward Wald method. Odds ratios (ORs) are presented with 95% confidence intervals (CIs). A p value <0.05 was considered statistically significant BMI SDS body mass index standard deviation score, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, WC waist circumference After backward Wald elimination, WC was the only remaining variable in the final multivariable model and was found to be significantly associated with high-grade pancreatic steatosis (OR: 64.22, 95% CI: 18.466–223.354; p < 0.001) (Table 3). Table 3Univariate and multivariable logistic regression analyses of factors associated with high-grade pancreatic steatosis in childrenVariablePancreatic steatosis grade 0–1 (n = 92)Pancreatic steatosis grade 2–3 (n = 71)Univariate OR (95% CI) p Multivariable OR (95% CI) p Age, years12 (4)12 (4)1.097 (0.957–1.258)0.183——Sex Female46 (50.0)24 (33.8)Reference——— Male46 (50.0)47 (66.2)1.958 (1.033–3.712)0.039——Hepatic steatosis grade1 (1)3 (1)5.804 (3.518–9.576)< 0.001——HOMA-IR4.06 (3.25)4.82 (3.81)1.011 (0.970–1.055)0.597——WC category <95th percentile68 (73.9)3 (4.2)Reference—Reference— ≥95th percentile24 (26.1)68 (95.8)64.22 (18.466–223.354)< 0.00164.22 (18.466–223.354)< 0.001Triglycerides, mg/dL113 (59.25)134 (77)1.009 (1.003–1.015)0.005——HDL-C, mg/dL44.5 (10)39 (9)0.947 (0.910–0.985)0.007——Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Univariate logistic regression was performed using the enter method. Variables with p<0.20 were included in the multiple logistic regression model using the backward Wald elimination method. Odds ratios (ORs) are presented with 95% confidence intervals (CIs). A p value <0.05 was considered statistically significantBMI SDS body mass index standard deviation score, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, WC waist circumference Table 3Univariate and multivariable logistic regression analyses of factors associated with high-grade pancreatic steatosis in childrenVariablePancreatic steatosis grade 0–1 (n = 92)Pancreatic steatosis grade 2–3 (n = 71)Univariate OR (95% CI) p Multivariable OR (95% CI) p Age, years12 (4)12 (4)1.097 (0.957–1.258)0.183——Sex Female46 (50.0)24 (33.8)Reference——— Male46 (50.0)47 (66.2)1.958 (1.033–3.712)0.039——Hepatic steatosis grade1 (1)3 (1)5.804 (3.518–9.576)< 0.001——HOMA-IR4.06 (3.25)4.82 (3.81)1.011 (0.970–1.055)0.597——WC category <95th percentile68 (73.9)3 (4.2)Reference—Reference— ≥95th percentile24 (26.1)68 (95.8)64.22 (18.466–223.354)< 0.00164.22 (18.466–223.354)< 0.001Triglycerides, mg/dL113 (59.25)134 (77)1.009 (1.003–1.015)0.005——HDL-C, mg/dL44.5 (10)39 (9)0.947 (0.910–0.985)0.007——Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Univariate logistic regression was performed using the enter method. Variables with p<0.20 were included in the multiple logistic regression model using the backward Wald elimination method. Odds ratios (ORs) are presented with 95% confidence intervals (CIs). A p value <0.05 was considered statistically significantBMI SDS body mass index standard deviation score, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, WC waist circumference Univariate and multivariable logistic regression analyses of factors associated with high-grade pancreatic steatosis in children Data are presented as median (interquartile range) for continuous variables and n (%) for categorical variables. Univariate logistic regression was performed using the enter method. Variables with p<0.20 were included in the multiple logistic regression model using the backward Wald elimination method. Odds ratios (ORs) are presented with 95% confidence intervals (CIs). A p value <0.05 was considered statistically significant BMI SDS body mass index standard deviation score, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, WC waist circumference There were significant differences across FE groups in hepatic steatosis grade, pancreatic steatosis grade, and WC category (all p < 0.001). Patients with low and severely low FE levels had a higher frequency of advanced hepatic and pancreatic steatosis grades compared with those with normal FE levels. Additionally, central obesity, defined as WC ≥ 95th percentile, was significantly more frequent in patients with reduced and severely reduced FE levels (Table 4). Table 4Comparison of clinical and imaging characteristics according to elastase groupsVariableNormal FE> 200 µg/g (n = 97)Low FE100–200 µg/g (n = 41)Severely low FE< 100 µg/g (n = 25) p Sex0.211 Female46 (47.4)17 (41.5)7 (28.0) Male51 (52.6)24 (58.5)18 (72.0)Hepatic steatosis grade< 0.001 159 (60.8)a7 (17.1)b5 (20)b 219 (19.6)a14 (34.1)a6 (24)a 319 (19.6)a20 (48.8)b14 (56)bPancreatic steatosis grade< 0.001 038 (39.2)a8 (19.5)ab2 (8.0)b 137 (38.1)a6 (14.6)b1 (4.0)b 218 (18.6)a19 (46.3)b15 (60.0)b 34 (4.1)a8 (19.5)b7 (28.0)bWC category< 0.001 <95th percentile60 (61.9)a7 (17.1)b4 (16.0)b ≥95th percentile37 (38.1)a34 (82.9)b21 (84.0)bData are presented as n (%). Comparisons among groups were performed using Pearson’s chi-square test. Different superscript letters indicate statistically significant differences between groups in post hoc pairwise comparisons, whereas identical letters indicate no statistically significant differenceFE fecal elastase, WC waist circumference Table 4Comparison of clinical and imaging characteristics according to elastase groupsVariableNormal FE> 200 µg/g (n = 97)Low FE100–200 µg/g (n = 41)Severely low FE< 100 µg/g (n = 25) p Sex0.211 Female46 (47.4)17 (41.5)7 (28.0) Male51 (52.6)24 (58.5)18 (72.0)Hepatic steatosis grade< 0.001 159 (60.8)a7 (17.1)b5 (20)b 219 (19.6)a14 (34.1)a6 (24)a 319 (19.6)a20 (48.8)b14 (56)bPancreatic steatosis grade< 0.001 038 (39.2)a8 (19.5)ab2 (8.0)b 137 (38.1)a6 (14.6)b1 (4.0)b 218 (18.6)a19 (46.3)b15 (60.0)b 34 (4.1)a8 (19.5)b7 (28.0)bWC category< 0.001 <95th percentile60 (61.9)a7 (17.1)b4 (16.0)b ≥95th percentile37 (38.1)a34 (82.9)b21 (84.0)bData are presented as n (%). Comparisons among groups were performed using Pearson’s chi-square test. Different superscript letters indicate statistically significant differences between groups in post hoc pairwise comparisons, whereas identical letters indicate no statistically significant differenceFE fecal elastase, WC waist circumference Comparison of clinical and imaging characteristics according to elastase groups Data are presented as n (%). Comparisons among groups were performed using Pearson’s chi-square test. Different superscript letters indicate statistically significant differences between groups in post hoc pairwise comparisons, whereas identical letters indicate no statistically significant difference FE fecal elastase, WC waist circumference In the MASLD group, the degree of pancreatic steatosis was significantly associated with low FE levels, whereas age, sex, BMI SDS, degree of hepatic steatosis, triglyceride levels, HDL-C, and HOMA-IR levels were not. None of the variables evaluated were significantly associated with high-grade pancreatic steatosis. Comparisons across FE categories also showed significant differences in the degree of pancreatic steatosis. Detailed results of these analyses, including the correlation analyses, are presented in Supplementary Tables S1–S3 and Supplementary Figure S1. ROC analysis demonstrated that pancreatic steatosis grade had the highest discriminative performance for detecting low FE levels (AUC = 0.760), followed by hepatic steatosis grade (AUC = 0.734), WC (AUC = 0.732), and BMI SDS (AUC = 0.673). The optimal cut-off value for pancreatic steatosis was identified as grade ≥ 2, which provided a sensitivity of 74.2% and a specificity of 77.3%. Hepatic steatosis grade ≥ 2 demonstrated high sensitivity (81.8%) but moderate specificity (60.8%). Laboratory-based metabolic parameters, including HOMA-IR, triglycerides, and ALT, showed only limited discriminative performance (Fig. 2). Fig. 2Receiver operating characteristic curves of clinical and imaging parameters for predicting low fecal elastase levels. Optimal cut-off values were determined using the Youden index. Low fecal elastase was defined as ≤ 200 µg/g. AUC: area under the curve; ALT: alanine aminotransferase; BMI SDS: body mass index standard deviation score; HOMA-IR: homeostatic model assessment of insulin resistance; WC: waist circumference Receiver operating characteristic curves of clinical and imaging parameters for predicting low fecal elastase levels. Optimal cut-off values were determined using the Youden index. Low fecal elastase was defined as ≤ 200 µg/g. AUC: area under the curve; ALT: alanine aminotransferase; BMI SDS: body mass index standard deviation score; HOMA-IR: homeostatic model assessment of insulin resistance; WC: waist circumference In the analysis limited to severely reduced FE levels (< 100 µg/g), pancreatic steatosis grade again demonstrated the best discriminative performance (AUC = 0.768), followed by WC (AUC = 0.681) and hepatic steatosis grade (AUC = 0.672). The optimal cut-off value for pancreatic steatosis remained grade ≥ 2, providing a sensitivity of 88.0% and a specificity of 64.5%. Grade ≥ 2 hepatic steatosis exhibited relatively lower discriminative capacity, whereas metabolic parameters had limited performance. These findings suggest that imaging-based markers, particularly pancreatic steatosis grade, may be more informative than metabolic markers for identifying children with markedly reduced FE levels (Fig. 3). Fig. 3ROC analysis of clinical and imaging parameters for severely reduced fecal elastase levels. Optimal cut-off values were determined using the Youden index. Sensitivity and specificity are presented as percentages. Severely low FE was defined as < 100 µg/g. AUC: area under the receiver operating characteristic curve; ALT: alanine aminotransferase; BMI SDS: body mass index standard deviation score; FE: fecal elastase; HOMA-IR: homeostatic model assessment of insulin resistance; WC: waist circumference ROC analysis of clinical and imaging parameters for severely reduced fecal elastase levels. Optimal cut-off values were determined using the Youden index. Sensitivity and specificity are presented as percentages. Severely low FE was defined as < 100 µg/g. AUC: area under the receiver operating characteristic curve; ALT: alanine aminotransferase; BMI SDS: body mass index standard deviation score; FE: fecal elastase; HOMA-IR: homeostatic model assessment of insulin resistance; WC: waist circumference Discussion In this study, we investigated the relationship between MASLD, pancreatic steatosis, and FE levels in a pediatric population. In the overall cohort, the degree of pancreatic steatosis was associated with low FE levels. Within the MASLD group, pancreatic steatosis grade was significantly associated with low FE levels, whereas age, sex, hepatic steatosis grade, BMI SDS, HOMA-IR, triglyceride levels, and HDL-C levels were not. These findings suggest that the association between pancreatic steatosis and low FE levels may not be explained solely by differences in metabolic characteristics. The increasing prevalence of childhood obesity has contributed to the growing burden of pediatric MASLD [15]. In our cohort, children with MASLD had higher BMI, BMI SDS, WC, blood pressure, triglyceride levels, HbA1c, plasma glucose, HOMA-IR, and ALT levels, together with lower HDL-C levels. The predominance of male patients in the MASLD group was consistent with previous evidence [16]. Current knowledge of MASLD has moved beyond a liver-limited condition toward a multisystem metabolic disorder [1, 3]. In this context, pancreatic steatosis has attracted interest as a potential extrahepatic manifestation of metabolic dysfunction. In an adult MASLD systematic review, the prevalence of fatty pancreas was reported as 54.32%, and pancreatic steatosis has been associated with greater cardiometabolic risk [17]. It has also been proposed that pancreatic steatosis may represent a possible marker for more detailed phenotypic classification and risk assessment in MASLD [16]. Consistently, the associations of higher triglyceride levels and lower HDL-C levels with both hepatic and pancreatic steatosis align with the literature and indicate that altered lipid metabolism may play a role in ectopic fat accumulation in the liver and pancreas [18]. However, pancreatic steatosis may reflect organ-specific implications rather than merely reflecting hepatic steatosis. Current evidence regarding the relationship between pancreatic steatosis and exocrine pancreatic function is limited [19]. Within the MASLD group, age, sex, degree of hepatic steatosis, BMI SDS, HOMA-IR, triglyceride levels, and HDL-C levels were not significantly associated with low FE levels. Thus, the association may not be explained solely by conventional metabolic parameters. Prior studies have proposed that pancreatic steatosis may adversely affect pancreatic beta-cell and islet-cell function, thereby contributing to hyperglycemia [20]. However, in the present cohort, pancreatic steatosis was not independently associated with glucose-related metabolic parameters. Beyond its possible functional implications, published data have shown that pancreatic steatosis is closely associated with fatty liver disease [21]. Furthermore, the risk of pancreatic steatosis has been reported to increase with the accumulation of metabolic syndrome components, with each additional component increasing this risk by approximately 37% [21]. The diagnosis and classification of pancreatic steatosis in childhood remain unstandardized, and age-specific imaging thresholds need to be established. Furthermore, there is no risk classification system specific to pancreatic steatosis. The lack of validated imaging criteria for pancreatic steatosis in children may increase the risk of misclassification, particularly in borderline grades, and limit reproducibility and generalizability. Furthermore, grading thresholds derived from adult populations may not correspond to equivalent degrees of pancreatic fat accumulation in children. Therefore, pediatric-specific imaging standards are needed, preferably validated against magnetic resonance imaging or other quantitative methods. The literature has reported a possible association between pancreatic steatosis and reduced exocrine pancreatic function. Previous studies have reported lower FE levels in patients with pancreatic steatosis [22]. Potential biological mechanisms may include local inflammation, lipotoxic injury, oxidative stress, and acinar cell damage, which may contribute to reduced enzyme secretion [23]. Because these mechanisms were not directly evaluated, this interpretation should be considered hypothesis-generating. The directionality and causality of the relationship between pancreatic steatosis, MASLD, and reduced FE levels are insufficiently understood. Demographic variations in fat distribution between the liver and pancreas remain insufficiently clarified. Although the clinical value of pancreatic steatosis as an independent marker for MASLD has not yet been fully established [17], our findings suggest an association between imaging-detected pancreatic steatosis and low FE levels in children. In our study, pancreatic steatosis grade remained independently associated with low FE levels in the overall cohort, whereas conventional metabolic parameters did not retain independent associations. Our findings suggest that pancreatic steatosis may be associated with alterations in a noninvasive marker of exocrine pancreatic function. Nevertheless, FE is an indirect marker, and pancreatic steatosis alone should not be interpreted as sufficient evidence of clinically overt exocrine pancreatic insufficiency. In the overall-cohort analysis, WC was the only variable retained in the final multivariable model for high-grade pancreatic steatosis. However, since WC ≥ 95th percentile was closely associated with the cardiometabolic definition of the study groups, the high OR value obtained should be interpreted cautiously in terms of independent clinical predictive value. None of the clinical and metabolic variables assessed for high-grade pancreatic steatosis were found to be significant in the MASLD group. This suggests that the determinants of pancreatic steatosis within MASLD may be more complex and that the strong WC association observed in the entire cohort may reflect significant anthropometric differences between groups as well as individual metabolic effects. In our study, imaging-based parameters, particularly pancreatic steatosis grade, demonstrated better discriminative performance than metabolic markers for identifying low FE levels. This finding suggests that imaging-based structural findings may provide additional information associated with low FE levels. Nevertheless, the current findings are not sufficient to support the use of pancreatic steatosis as a validated risk stratification tool or routine screening for exocrine pancreatic function. A major strength of this study is the simultaneous evaluation of hepatic steatosis, pancreatic steatosis, metabolic parameters, and FE levels in a pediatric cohort. In addition, separate analyses within the MASLD group allowed evaluation of the relationship between pancreatic steatosis and low FE levels within a clinically relevant population. However, the present study has several limitations. First, the cross-sectional design restricts the ability to determine temporal associations. Second, pancreatic steatosis was assessed by ultrasonography, for which no validated pediatric grading criteria are available. This may have introduced misclassification, particularly in borderline cases, and adult-derived thresholds may not correspond to equivalent degrees of pancreatic fat accumulation in children. Third, FE is an indirect marker of exocrine pancreatic function and was measured in a single stool sample. Stool consistency was not recorded using a validated scale, and sampling time and stool weight were not standardized. Accordingly, low FE levels cannot reliably distinguish true functional impairment from dilution or measurement-related effects, while normal FE levels may not completely exclude mild or early exocrine pancreatic insufficiency. Fourth, because WC ≥ 95th percentile was closely related to the cardiometabolic characterization of the study groups, its association with study outcomes should be interpreted cautiously with regard to independent clinical predictive value. Finally, no a priori sample size calculation was performed, and the study was conducted at a single center. Nevertheless, all consecutive patients during the study period were included. Conclusions Pancreatic steatosis was more frequent in children with MASLD, and its severity was associated with low FE levels both in the overall cohort and in the MASLD group. Imaging-based findings, particularly pancreatic steatosis, showed moderate discriminatory performance for low FE levels; however, these findings should not be interpreted as validated diagnostic thresholds. Overall, pancreatic steatosis may represent a clinically relevant feature of pediatric MASLD, particularly in relation to alterations in exocrine pancreatic function. Prospective studies using standardized imaging methods and longitudinal functional assessment are needed to clarify the clinical significance and outcomes of this association. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3. Supplementary Material 4. Supplementary Material 4.